文献速递角膜与眼表疾病

新型肌醇酰基转移酶(Gwt1)抑制剂Manogepix治疗真菌性角膜炎的体内外疗效与安全性评价

Novel Inositol Acyltransferase (Gwt1) Inhibitor for Fungal Keratitis Treatment: Evaluation of In Vitro and In Vivo Efficacy and Safety.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究评估了首创新药Gwt1真菌酶抑制剂Manogepix(MGX)治疗真菌性角膜炎的潜力。体外实验显示MGX对白色念珠菌具有杀菌活性,对茄病镰刀菌和黄曲霉具有抑菌活性,并能抑制生物膜形成、破坏真菌形态,与两性霉素B有协同/相加作用。兔茄病镰刀菌角膜炎模型中,局部滴用MGX可减轻临床表现并显著降低CFU计数,且体外和体内均显示良好的眼安全性。

要点

  • MGX对白色念珠菌MIC₉₀为0.0313 µg/mL、MFC₉₀为0.156 µg/mL,对茄病镰刀菌IC₈₀为0.019-0.312 µg/mL,对黄曲霉IC₈₀为1.25-20 µg/mL。
  • MGX在MIC和IC80浓度下抑制生物膜形成、破坏真菌细胞形态和增殖动力学,与两性霉素B呈协同/相加效应。
  • 兔茄病镰刀菌角膜炎模型中,局部MGX(50 µL,0.01% w/v,8次/日,4天)减轻临床表现并显著降低CFU计数。

核心结论

  • MGX对主要眼部真菌病原体具有疗效,并在体外和体内模型中显示良好的眼安全性。

研究设计与样本

  • 体外评估MGX对白色念珠菌(n=10)、茄病镰刀菌(n=8)和黄曲霉(n=6)临床角膜炎分离株的MIC、MFC、生物膜抑制、形态变化、时间-杀菌动力学及与两性霉素B的相互作用。
  • 在体外人角膜上皮细胞(HCEC)和体内Draize试验中评估安全性。
  • 在兔茄病镰刀菌角膜炎模型中评估体内疗效,动物接受局部MGX(50 µL,0.01% w/v,8次/日)治疗四天,随后进行临床评分、CFU计数和组织病理学分析。

主要发现

  • MGX对白色念珠菌具有杀菌活性(MIC₉₀:0.0313,MFC₉₀:0.156 µg/mL),对茄病镰刀菌和黄曲霉具有抑菌活性,IC₈₀范围分别为0.019-0.312和1.25-20 µg/mL。
  • 在MIC和IC80浓度下,MGX抑制生物膜形成、破坏真菌细胞形态和增殖动力学。
  • MGX与两性霉素B表现出协同/相加效应。
  • MGX在体外5 µg/mL浓度下对HCEC安全,在体内100 µg/mL浓度下未显示角膜毒性迹象。
  • 在兔茄病镰刀菌角膜炎模型中,MGX治疗减轻了FK的临床表现,与未治疗对照组相比显著降低了CFU计数。

关键数值与推荐

  • MGX对白色念珠菌MIC₉₀为0.0313 µg/mL,MFC₉₀为0.156 µg/mL。
  • MGX对茄病镰刀菌IC₈₀范围为0.019-0.312 µg/mL,对黄曲霉IC₈₀范围为1.25-20 µg/mL。
  • 体外安全性评估中MGX在5 µg/mL浓度下对HCEC安全。
  • 体内安全性评估中MGX在100 µg/mL浓度下未显示角膜毒性。
  • 兔模型局部给药方案为50 µL,0.01% w/v,8次/日,持续四天。

临床怎么用

  • MGX作为首创新药Gwt1抑制剂,对白色念珠菌、茄病镰刀菌和黄曲霉等眼部真菌病原体具有体外活性。
  • MGX与两性霉素B联用显示协同/相加效应,提示潜在联合治疗价值。
  • 兔模型结果支持局部MGX治疗茄病镰刀菌角膜炎可减轻临床表现并降低真菌负荷。
  • 体外和体内安全性数据支持MGX在测试浓度下具有良好的眼安全性特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fungal keratitis (FK) is a vision-threatening infection affecting ∼1 million people annually. This study assesses the therapeutic potential of Manogepix (MGX), a first-in-class Gwt1 fungal enzyme inhibitor, using in vitro and in vivo models. METHODS: MGX's in vitro efficacy was evaluated against clinical keratitis isolates of Candida albicans (n = 10), Fusarium solani (n = 8), and Aspergillus flavus (n = 6) by determining minimal inhibitory and fungicidal concentrations (MIC and MFC), biofilm inhibition, morphological changes, time-kill kinetics at MIC and interaction with amphotericin B. Safety was assessed in vitro on human corneal epithelial cells (HCECs) and in vivo via Draize's test. In vivo efficacy was evaluated in a rabbit F. solani keratitis model. Animals received topical MGX (50 µL, 0.01% w/v, 8×/day) for four days, followed by clinical scoring, colony-forming unit (CFU) enumeration, and histopathological analysis. RESULTS: MGX was fungicidal against C. albicans (MIC₉₀: 0.0313, MFC₉₀: 0.156 µg/mL) and fungistatic against F. solani and A. flavus, with IC₈₀ ranges of 0.019-0.312 and 1.25-20 µg/mL, respectively. At MIC and IC80, MGX inhibited biofilm formation, disrupted fungal cellular morphology and proliferation dynamics. MGX exhibited synergistic/additive effects with amphotericin B. MGX was found safe in vitro at 5 µg/mL on HCECs and showed no signs of corneal toxicity in vivo at 100 µg/mL. In the rabbit model F. solani keratitis, MGX treatment reduced the clinical manifestations of FK and significantly reduced CFU counts compared with untreated controls. CONCLUSIONS: MGX demonstrated efficacy against major ocular fungal pathogens and showed a favorable ocular safety profile in both in vitro and in vivo models.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Gowtham L, Meghana Y, Mannangatty T, et al. Novel Inositol Acyltransferase (Gwt1) Inhibitor for Fungal Keratitis Treatment: Evaluation of In Vitro and In Vivo Efficacy and Safety. Invest Ophthalmol Vis Sci. 2026. PMID: 42012271. doi:10.1167/iovs.67.4.49

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。